EGFR as a potential target for the treatment of pancreatic cancer: Dilemma and controversies

Current Drug Targets

Volumn 15, Issue 14, 2014, Pages 1293-1301

  Nedaeinia, Reza ^a   Avan, Amir ^a   Manian, Mostafa ^b   Salehi, Rasoul ^b   Ghayour Mobarhan, Majid ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

EGFR; EGFR targeted therapies; Pancreatic cancer; Resistance mechanisms

Indexed keywords

AFATINIB; AMPHIREGULIN; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; METFORMIN; OXALIPLATIN; PILARALISIB; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UFT; VARLITINIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LUNG CANCER; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PANCREATIC NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84920626469     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141125123003     Document Type: Article

References (75)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703.
4. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptortargeted therapy for pancreatic cancer. Semin Oncol 2002; 29:31-7.
5. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203-12.
6. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8:11-31
7. Mendelsohn J, Baird A, Fan Z, Markowitz S. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J, Howley, PM, Israel MA, Liotta, LA. The molecular basis of cancer. 2nd ed. Philadelphia, PA: WB Saunders, 2001. Chapter 8. 137-61
8. Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. Jop 2007; 8:4-15.
9. Frolov A, Schuller K, Tzeng CW, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007; 6:548-54.
10. Ioannou N, Dalgleish AG, Seddon AM, et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Bri J Cancer 2011; 105: 1554-62.
11. Liles JS, Arnoletti JP, Kossenkov AV, et al. Targeting ErbB3- mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Bri J Cancer 2011; 105:523-33.
12. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Inves New Drugs 1999; 17:259-69.
13. Boeck S, Jung A, Laubender RP, et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Bri J Cancer 2013; 108:469-76.
14. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Bio 2006; 7:505-16.
15. Lemoine NR, Hughes CM, Barton CM, et al.The epidermal growth factor receptor in human pancreatic cancer. J Path 1992; 166:7-12.
16. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anti Res 1993; 13:565-9.
17. Dong M, Nio Y, Guo KJ, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anti Res 1998; 18:4613-9.
18. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Bio Cell 1993; 4:121-33.
19. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232:1250-3.
20. Uegaki K, Nio Y, Inoue Y, et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anti Res 1997; 17:3841-7.
21. Abbruzzese J, Rosenberg A, Xiong Q, et al. Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Cetuximab (IMC-C225) in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. J Clin Oncol 2001; 20:518.
22. Funel N, Vasile E, Del Chiaro M, et al. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Ann Oncol 2011; 22:482-4.
23. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926-35.
24. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007; 39: 1416-31.
25. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006; 12:4441s-5.
26. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18:427-36.
27. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355-62.
28. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936-48.
29. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89:74-82.
30. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, et al.Cetuximab, a monoclonal antibody targeting the epidermalgrowth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22:2610-6.
31. Philip P, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]. J Clin Oncol 2007; 25:4509.
32. Burtness A. Randomized phase II trial of docetaxel, irinotecan and cetuximab in metastatic pancreatic cancer. J Clin Oncol 2007; 25:202S.
33. Pipas J, Zaki B, McGowan M, et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol 2012; 23:2820-7
34. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
35. Renouf DJ, Tang PA, Hedley D, et al.A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer 2014; 50:1909-15.
36. Epelbaum R, Schnaider J, Gluzman A, Figer A. Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, FL; 2007.
37. Kulke MH1, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787-92.
38. Watkins D, Starling N, Cunningham D, et al. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. Eur J Cancer 2014; 50:1422-9.
39. Propper D, Davidenko I, Bridgewater J, et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol 2014; 25:1384-90.
40. Safran H, Miner T, Bahary N, et al. Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. Am J Clin Oncol 2011; 34:50-2.
41. Brell JM, Matin K, Evans T, et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76:270-4.
42. Ignatiadis M, Polyzos A, Stathopoulos GP, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2007; 71:159-63.
43. Moore M, da Cunha Santos G, Kamel-Reid S, et al. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA. 3. J Clin Oncol 2007; 25: 4521.
44. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8:S7-14.
45. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24:1807-13.
46. Chua Y, Zalcberg J. Pancreatic cancer—is the wall crumbling? Ann Oncol 2008; 19: 1224-30.
47. Slebos RJ, Hoppin JA, Tolbert PE, et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9:1223-32.
48. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer ther 2005; 4:677-85.
49. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-7.
50. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
51. Renouf D, Tang P, Hedley D, et al. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer 2014; 50:1909-15
52. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
53. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007; 14:224-32
54. Avan A, Caretti V, Funel N, et al. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res 2013; 73:6745-56.
55. Giovannetti E, Wang Q, Avan A, et al. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst 2014; 106:djt346.
56. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6.
57. Wong MH, Xue A, Julovi SM, et al. Co-targeting of epidermal growth factor receptor (EGFR) and PI3K overcomes PI3K/Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clin Cancer Res 2014.
58. Al-Ejeh F, Pajic M, Shi W, et al. Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2014; 20:3187-97.
59. Bokemeyer C, Bondarenko I, Hartmann J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26:4000.
60. Jackman D, Sequist L, Cioffredi L, et al. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol 2008; 26:8035.
61. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic acids Res 1988; 16:7773-82.
62. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54.
63. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68:1953-61.
64. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-19.
65. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-22.
66. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
67. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-56.
68. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Bio Cell 1999; 10:2493- 506.
69. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935-40.
70. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 2005; 28:570-5.
71. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 2006; 65:1192-9.
72. Lammering G, Valerie K, Lin PS, et al. Radiosensitization of malignant glioma cells through overexpression of dominantnegative epidermal growth factor receptor. Clin Cancer Res 2001; 7:682-90.
73. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiationinduced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15:1191-7.
74. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008; 19:86-91.
75. Krempien R, Muenter MW, Huber PE, et al. Randomized phase II- -study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. BMC Cancer 2005; 5:131.